Advanced

Riskstratifiering vid pulmonell arteriell hyper­tension - Ger bättre behandling och prognos – högspecialiserat omhändertagande vid universitetssjukhusen krävs

Rådegran, Göran LU (2018) In Lakartidningen 115.
Abstract

Pulmonary arterial hypertension (PAH) is a progressive vascular disease, due to vasoconstriction and remodelling of pulmonary arteries. Survival has from diagnosis, if untreated, been found to be 1 to 2.8 years, depending on whether related to rheumatic disease or not. The ESC/ERS risk stratification tool provides a new approach to evaluate the clinical status of PAH patients. It supports a refined treatment strategy, based on risk assessment at diagnosis and early follow-up, with the aim to identify patients early and initiate, as well as adjust treatment individually, striving for the patients to remain in, or improve to low risk status, whereby survival is markedly improved.

Please use this url to cite or link to this publication:
author
organization
alternative title
Riskstratification in pulmonary arterial hypertension - renders better treatment and prognosis at highly specialised centers
publishing date
type
Contribution to journal
publication status
published
subject
in
Lakartidningen
volume
115
publisher
Swedish Medical Association
external identifiers
  • scopus:85054898463
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
83d09630-fbf1-4210-abe7-80e7844268e9
alternative location
http://lakartidningen.se/Klinik-och-vetenskap/Kommentar/2018/10/Riskstratifiering-vid-pulmonell-arteriell-hypertension/
date added to LUP
2018-10-30 11:58:30
date last changed
2019-02-20 11:33:55
@article{83d09630-fbf1-4210-abe7-80e7844268e9,
  abstract     = {<p>Pulmonary arterial hypertension (PAH) is a progressive vascular disease, due to vasoconstriction and remodelling of pulmonary arteries. Survival has from diagnosis, if untreated, been found to be 1 to 2.8 years, depending on whether related to rheumatic disease or not. The ESC/ERS risk stratification tool provides a new approach to evaluate the clinical status of PAH patients. It supports a refined treatment strategy, based on risk assessment at diagnosis and early follow-up, with the aim to identify patients early and initiate, as well as adjust treatment individually, striving for the patients to remain in, or improve to low risk status, whereby survival is markedly improved.</p>},
  author       = {Rådegran, Göran},
  issn         = {0023-7205},
  language     = {swe},
  month        = {10},
  publisher    = {Swedish Medical Association},
  series       = {Lakartidningen},
  title        = {Riskstratifiering vid pulmonell arteriell hyper­tension - Ger bättre behandling och prognos – högspecialiserat omhändertagande vid universitetssjukhusen krävs},
  volume       = {115},
  year         = {2018},
}